SG11201907738UA - Ranking system for immunogenic cancer-specific epitopes - Google Patents

Ranking system for immunogenic cancer-specific epitopes

Info

Publication number
SG11201907738UA
SG11201907738UA SG11201907738UA SG11201907738UA SG11201907738UA SG 11201907738U A SG11201907738U A SG 11201907738UA SG 11201907738U A SG11201907738U A SG 11201907738UA SG 11201907738U A SG11201907738U A SG 11201907738UA SG 11201907738U A SG11201907738U A SG 11201907738UA
Authority
SG
Singapore
Prior art keywords
international
dist
rule
taipei city
epitopes
Prior art date
Application number
SG11201907738UA
Other languages
English (en)
Inventor
Yang Pei-Jia
Jen-Hao Cheng
Ying-Ja Chen
Shu-Jen Chen
Hua-Chien Chen
Original Assignee
Pei Jia Yang
Cheng Jen Hao
Chen Ying Ja
Chen Shu Jen
Chen Hua Chien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pei Jia Yang, Cheng Jen Hao, Chen Ying Ja, Chen Shu Jen, Chen Hua Chien filed Critical Pei Jia Yang
Publication of SG11201907738UA publication Critical patent/SG11201907738UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Data Mining & Analysis (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Artificial Intelligence (AREA)
SG11201907738UA 2017-03-31 2018-03-31 Ranking system for immunogenic cancer-specific epitopes SG11201907738UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479320P 2017-03-31 2017-03-31
PCT/US2018/025597 WO2018183980A2 (en) 2017-03-31 2018-03-31 Ranking system for immunogenic cancer-specific epitopes

Publications (1)

Publication Number Publication Date
SG11201907738UA true SG11201907738UA (en) 2019-09-27

Family

ID=63676910

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907738UA SG11201907738UA (en) 2017-03-31 2018-03-31 Ranking system for immunogenic cancer-specific epitopes

Country Status (7)

Country Link
US (1) US11485784B2 (https=)
EP (1) EP3600340A4 (https=)
JP (1) JP7155470B2 (https=)
CN (1) CN110799196B (https=)
SG (1) SG11201907738UA (https=)
TW (1) TWI672503B (https=)
WO (1) WO2018183980A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2729116C2 (ru) * 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
KR102841050B1 (ko) * 2017-04-19 2025-08-01 그릿스톤 바이오, 인코포레이티드 신생항원 동정, 제조, 및 용도
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
CA3115017C (en) * 2018-11-21 2023-10-31 Nec Corporation Method and system of targeting epitopes for neoantigen-based immunotherapy
AU2019404547B2 (en) * 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
WO2020174077A1 (en) 2019-02-28 2020-09-03 Universiteit Antwerpen Method for determining responsiveness to an epitope
US20220208306A1 (en) * 2019-04-30 2022-06-30 Memorial Sloan Kettering Cancer Center System and methods for identification of non-immunogenic epitopes and determining efficacy of epitopes in therapeutic regimens
CN115917654A (zh) * 2020-04-21 2023-04-04 瑞泽恩制药公司 用于分析受体相互作用的方法和系统
JP2024508677A (ja) * 2021-02-05 2024-02-28 アマゾン テクノロジーズ インコーポレイテッド 個別化がんワクチン用ネオアンチゲンのランク付け
US12518851B2 (en) * 2021-09-07 2026-01-06 Nec Corporation Binding peptide generation for MHC class I proteins with deep reinforcement learning for immunotherapy decision making
CN118302816A (zh) * 2021-09-28 2024-07-05 行动基因(智财)有限公司 甲基化生物标记选择装置及方法
WO2025217519A1 (en) * 2024-04-12 2025-10-16 Foundation Medicine, Inc. Clonal neoantigen burden as a biomarker of immunotherapy response

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005301523A (ja) * 2004-04-08 2005-10-27 Celestar Lexico-Sciences Inc ワクチン候補部分配列予測装置、ワクチン候補部分配列予測方法、ｍｈｃ結合部分配列予測装置、ｍｈｃ結合部分配列予測方法、プログラムおよび記録媒体
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
CN118750591A (zh) * 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
EP3194970B1 (en) * 2014-09-10 2021-07-28 F. Hoffmann-La Roche AG Immunogenic mutant peptide screening platform
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
CN107750278B (zh) 2015-04-27 2023-10-03 癌症研究技术有限公司 治疗癌症的方法
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CN107704727B (zh) * 2017-11-03 2020-01-31 杭州风起智能科技有限公司 基于肿瘤新抗原特征值的新抗原活性预测和排序方法

Also Published As

Publication number Publication date
WO2018183980A3 (en) 2018-12-20
EP3600340A2 (en) 2020-02-05
US11485784B2 (en) 2022-11-01
TW201903411A (zh) 2019-01-16
JP7155470B2 (ja) 2022-10-19
CN110799196B (zh) 2024-02-13
US20210284738A1 (en) 2021-09-16
EP3600340A4 (en) 2021-01-20
CN110799196A (zh) 2020-02-14
JP2020518083A (ja) 2020-06-18
WO2018183980A2 (en) 2018-10-04
TWI672503B (zh) 2019-09-21

Similar Documents

Publication Publication Date Title
SG11201907738UA (en) Ranking system for immunogenic cancer-specific epitopes
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201909949XA (en) Targeted immunotolerance
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201808797XA (en) T cell receptors
SG11201903737PA (en) Neutralizing anti-tl1a monoclonal antibodies
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201811408PA (en) Adoptive cell transfer and oncolytic virus combination therapy
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201804259UA (en) Antibody cytokine engrafted compositions and methods of use for immunoregulation
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease